03.09.2024 - 05.09.2024The Royal Sonesta Boston, 40 Edwin H Land Boulevard, 02142 Cambridge, Massachusetts, USA
Time: 9:00 AM - 5:00 PM
Temi della conferenza As of 2023, more than 10 bispecific antibodies have been successfully approved by the FDA, and more than 100 are currently in clinical trials, highlighting biopharma’s continued investment within bispecific therapeutics.
